AIF1 and myeloid sarcoma: For MS, baicalein alleviates disease severity by reducing Th1 and Th17 cell migration and impairing microglia activation (73), and improves cuprizone-induced EAE mice by inhibiting the ionized calcium binding adapter molecule 1 (Iba1)-positive microglia (74).